Blog
RSS FeedPosted by Michael Wonder on 01 Feb 2023
Somatrogon for treating growth disturbance in people 3 years and over
1 February 2023 - Somatrogon is recommended as an option for the treatment of children 3 years of age and over ...
Posted by Michael Wonder on 01 Feb 2023
Upadacitinib monohydrate for the treatment of patients with active non-radiographic axial spondyloarthritis
1 February 2023 - Upadacitinib monohydrate is recommended as an option for the treatment of adults with active non-radiographic axial ...
Posted by Michael Wonder on 31 Jan 2023
Jazz Pharmaceuticals receives NICE recommendation for the reimbursement of Epidyolex (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex in England
31 January 2023 - Jazz Pharmaceuticals today announced that Epidyolex (cannabidiol 100 mg/mL oral solution), developed by GW Pharmaceuticals, has been ...
Posted by Michael Wonder on 27 Jan 2023
Risankizumab for the treatment of patients with previously treated moderate to severe active Crohn's disease
27 January 2023 - The Department of Health and Social Care has asked NICE to produce guidance on using risankizumab in ...
Posted by Michael Wonder on 26 Jan 2023
More than 400 people set to benefit after NICE approves ground-breaking CAR-T therapy to treat aggressive form of blood cancer
26 January 2023 - Hundreds of people with an aggressive form of lymphoma are set to benefit from the first ...
Posted by Michael Wonder on 25 Jan 2023
NICE approves new migraine drug for NHS use in England and Wales
25 January 2023 - Drugs regulator recommends eptinezumab for adults when three previous treatments have failed. ...
Posted by Michael Wonder on 19 Jan 2023
NICE backs Alnylam’s Amvuttra for rare form of amyloidosis
19 January 2023 - Alnylam’s gene-silencing drug Amvuttra has been recommended as a treatment for hereditary transthyretin-related amyloidosis by NICE, ...
Posted by Michael Wonder on 19 Jan 2023
NICE recommends reimbursement for Translarna
19 January 2023 - Only approved treatment for the underlying cause of nonsense mutation Duchenne muscular dystrophy. ...
Posted by Michael Wonder on 18 Jan 2023
Voxelotor for the treatment of patients with sickle cell disease
11 January 2023 - The Department of Health and Social Care has asked NICE to produce guidance on using voxelotor ...
Posted by Michael Wonder on 18 Jan 2023
Maribavir for the treatment of patients with a refractory cytomegalovirus infection after transplant
18 January 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 16 Jan 2023
Angiotensin II acetate for the treatment of patients with vasosuppressor-resistant hypotension caused by septic or distributive shock
16 January 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 11 Jan 2023
Nivolumab in combination with platinum and fluoropyrimidine-based chemotherapy for the first-line treatment of patients with advanced, HER2 negative gastric, gastro-oesophageal junction or oesophageal adenocarcinoma
11 January 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 04 Jan 2023
Mobocertinib succinate for patients with advanced EGFR exon 20 insertion mutation positive non-small-cell lung cancer after platinum-based chemotherapy
4 January 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 22 Dec 2022
NICE recommends a weekly injection for treating growth failure in children
22 December 2022 - This recommendation comes from a pilot to develop simpler, faster evaluations for the appraisal of some treatments. ...
Posted by Michael Wonder on 20 Dec 2022
NICE recommends Enhertu for more people with advanced breast cancer
20 December 2022 - Hundreds more people eligible for breast cancer drug Enhertu as NICE recommends it for earlier stage ...